Prescribing information

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

PIQRAY® is given in combination with fulvestrant.   

Dosing and administration1

Continue treatment until disease progression or until unacceptable toxicity occurs.

*Tablets should not be chewed, crushed or split prior to swallowing. No tablet should be ingested if it is broken, cracked, or otherwise not intact.

Accounting for missed doses

If a dose is missed, it can be taken immediately following food and within 9 hours after the time it is usually administered. After more than 9 hours, the dose should be skipped on that day. The next day, PIQRAY® should be taken at its usual time.

If the patient vomits after taking the dose, the patient should not take an additional dose on that day, and should resume the usual dosing schedule the next day at the usual time.

Certain AEs may require dose modifications

 

Screenshot from the video: Professor Caroline Robert discusses the landmark 5-year data with Tafinlar + Mekinist

THERAPY MANAGEMENT GUIDE

Please see the therapy management guide for more details on dosing and administration.

View resources 

The blister pack is designed to help patients stay on track with treatment

Dosing table. The recommended starting dose of PIQRAY: 300 mg daily + Fulvestrant recommended dose 500 mg

 

AE, adverse event.

Reference     

  1. PIQRAY® (alpelisib) Summary of Product Characteristics. Novartis Pharma; 2020.
HCP20-C003 September 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]